{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:44:31Z","timestamp":1792619071617,"version":"4.5.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.euf.2024.09.012","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T21:39:24Z","timestamp":1727559564000},"page":"323-336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Mirabegron Versus Placebo and Other Therapeutic Modalities in the Treatment of Patients with Overactive Bladder Syndrome\u2014A Systematic Review"],"prefix":"10.1016","volume":"11","author":[{"given":"Anirban","family":"Dey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Georgiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Umezurike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fawzy","family":"Farag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"N\u2019Dow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Imran","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Mamoulakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2024.09.012_b0005","first-page":"387","article-title":"Comparison of two different drugs for overactive bladder, solifenacin and mirabegron: a prospective randomized crossover study","volume":"73","author":"Inoue","year":"2019","journal-title":"Acta Med Okayama"},{"key":"10.1016\/j.euf.2024.09.012_b0010","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/nau.22609","article-title":"Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013","volume":"33","author":"Drake","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2024.09.012_b0015","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/JU.0000000000000309","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment 2019","volume":"202","author":"Lightner","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2024.09.012_b0020","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.eururo.2022.05.012","article-title":"European Association of Urology guidelines on male urinary incontinence","volume":"82","author":"Gacci","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.09.012_b0025","series-title":"Presented at the EAU Annual Congress, Paris","article-title":"EAU Guidelines On Non-Neurogenic Female LUTS","author":"Harding","year":"2024"},{"key":"10.1016\/j.euf.2024.09.012_b0030","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.urology.2011.09.010","article-title":"Racial differences in the prevalence of overactive bladder in the United States from the Epidemiology of LUTS (EpiLUTS) study","volume":"79","author":"Coyne","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.euf.2024.09.012_b0035","first-page":"10","article-title":"Risk factors of overactive bladder syndrome and its relation to sexual function in menopausal women","volume":"85","author":"Hakimi","year":"2018","journal-title":"Urol J"},{"key":"10.1016\/j.euf.2024.09.012_b0040","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.eururo.2023.04.008","article-title":"Summary Paper on the 2023 European Association of Urology guidelines on the management of non-neurogenic male lower urinary tract symptoms","volume":"84","author":"Gravas","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.09.012_b0045","series-title":"Presented at the EAU Annual Congress, Paris","article-title":"EAU guidelines on non-neurogenic male lower urinary tract symptoms (LUTS)","author":"Cornu","year":"2024"},{"key":"10.1016\/j.euf.2024.09.012_b0050","first-page":"S98","article-title":"Impact of overactive bladder on work productivity in the United States: results from EpiLUTS","volume":"15","author":"Sexton","year":"2009","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.euf.2024.09.012_b0055","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1464-410X.2005.05889.x","article-title":"Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries","volume":"97","author":"Irwin","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2024.09.012_b0060","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.eururo.2018.03.020","article-title":"Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis","volume":"74","author":"Kelleher","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.09.012_b0065","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/bju.13945","article-title":"Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis","volume":"120","author":"Drake","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2024.09.012_b0070","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/nau.22505","article-title":"Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability","volume":"33","author":"Chapple","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2024.09.012_b0075","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.euf.2021.08.011","article-title":"Choosing the most efficacious and safe oral treatment for idiopathic overactive bladder: a systematic review and network meta-analysis","volume":"8","author":"Mostafaei","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2024.09.012_b0080","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.eururo.2013.11.010","article-title":"Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison","volume":"65","author":"Maman","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.09.012_b0085","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1159\/000361079","article-title":"The role of mirabegron in overactive bladder: a systematic review and meta-analysis","volume":"93","author":"Wu","year":"2014","journal-title":"Urol Int"},{"key":"10.1016\/j.euf.2024.09.012_b0090","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11255-013-0509-9","article-title":"The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials","volume":"46","author":"Cui","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.euf.2024.09.012_b0095","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.eururo.2023.05.014","volume":"84","author":"Farag","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.09.012_b0100","series-title":"Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023)","year":"2023"},{"key":"10.1016\/j.euf.2024.09.012_b0105","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.eururo.2017.08.016","article-title":"Key steps in conducting systematic reviews for underpinning clinical practice guidelines: methodology of the European Association of Urology","volume":"73","author":"Knoll","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.09.012_b0110","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2024.09.012_b0115","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/nau.20798","article-title":"An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction","volume":"29","author":"Haylen","year":"2010","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2024.09.012_b0120","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2014.02.012","article-title":"Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony)","volume":"67","author":"Abrams","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.09.012_b0125","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00345-016-1908-1","volume":"35","author":"Abrams","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2024.09.012_b0130","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00192-013-2042-x","article-title":"A phase II dose-ranging study of mirabegron in patients with overactive bladder","volume":"24","author":"Chapple","year":"2013","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.euf.2024.09.012_b0135","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.urology.2013.02.077","article-title":"A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the \u03b23 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder","volume":"82","author":"Herschorn","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.euf.2024.09.012_b0140","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/bju.13882","article-title":"Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study)","volume":"120","author":"Herschorn","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2024.09.012_b0145","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/nau.23315","article-title":"Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients","volume":"37","author":"Robinson","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2024.09.012_b0150","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/MBP.0000000000000320","article-title":"A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of non-cardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial","volume":"23","author":"Weber","year":"2018","journal-title":"Blood Press Monit"},{"key":"10.1016\/j.euf.2024.09.012_b0155","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/jcph.1107","article-title":"Cardiovascular safety of the \u03b23-adrenoceptor agonist mirabegron and the antimuscarinic agent solifenacin in the SYNERGY trial","volume":"58","author":"White","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.euf.2024.09.012_b0160","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.eururo.2019.10.002","article-title":"Efficacy, safety, and tolerability of mirabegron in patients aged \u226565yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR)","volume":"77","author":"Wagg","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.09.012_b0165","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s40266-020-00783-w","article-title":"Safety and tolerability results from the PILLAR study: a phase IV, double-blind, randomized, placebo-controlled study of mirabegron in patients \u226565 years with overactive bladder-wet","volume":"37","author":"Herschorn","year":"2020","journal-title":"Drugs Aging"},{"key":"10.1016\/j.euf.2024.09.012_b0170","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12877-020-1474-7","article-title":"Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR)","volume":"20","author":"Griebling","year":"2020","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.euf.2024.09.012_b0175","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/luts.12053","article-title":"Efficacy and safety of the selective \u03b23-adrenoceptor agonist mirabegron in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled, dose-finding study","volume":"7","author":"Yamaguchi","year":"2015","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.euf.2024.09.012_b0180","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","article-title":"Efficacy and tolerability of mirabegron, a \u03b23-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial","volume":"63","author":"Khullar","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.09.012_b0185","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2490-13-45","article-title":"Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian phase 3 trial","volume":"13","author":"Khullar","year":"2013","journal-title":"BMC Urol"},{"key":"10.1016\/j.euf.2024.09.012_b0190","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/nau.22844","article-title":"Patient-reported outcomes with the \u03b23-adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder","volume":"35","author":"Khullar","year":"2016","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2024.09.012_b0195","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.urols.2014.12.010","article-title":"Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials","volume":"26","author":"Kuo","year":"2015","journal-title":"Urol Sci"},{"key":"10.1016\/j.euf.2024.09.012_b0200","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/nau.22645","article-title":"Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a \u03b23-adrenoceptor agonist, in patients with overactive bladder in Asia","volume":"34","author":"Kuo","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2024.09.012_b0205","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.juro.2012.10.017","article-title":"Results of a randomized phase III trial of mirabegron in patients with overactive bladder","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2024.09.012_b0210","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/nau.23852","article-title":"Mirabegron as a treatment for overactive bladder symptoms in men (MIRACLE study): efficacy and safety results from a multicenter, randomized, double-blind, placebo-controlled, parallel comparison phase IV study","volume":"38","author":"Shin","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2024.09.012_b0215","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/luts.12384","article-title":"Adding mirabegron after intravesical onabotulinumtoxinA injection improves therapeutic effects in patients with refractory overactive bladder","volume":"13","author":"Wang","year":"2021","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.euf.2024.09.012_b0220","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/bju.12649","article-title":"Phase III, randomised, double-blind, placebo-controlled study of the \u03b23-adrenoceptor agonist mirabegron, 50\u00a0mg once daily, in Japanese patients with overactive bladder","volume":"113","author":"Yamaguchi","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2024.09.012_b0225","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.archger.2015.06.006","article-title":"A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron","volume":"61","author":"Kosilov","year":"2015","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.euf.2024.09.012_b0230","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/iju.13231","article-title":"Comparison of mirabegron and imidafenacin for efficacy and safety in Japanese female patients with overactive bladder: a randomized controlled trial (COMFORT study)","volume":"23","author":"Otsuka","year":"2016","journal-title":"Int J Urol"},{"key":"10.1016\/j.euf.2024.09.012_b0235","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/nau.23050","article-title":"Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: a randomized crossover study (the MICRO study)","volume":"36","author":"Torimoto","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2024.09.012_b0240","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00192-017-3377-5","article-title":"A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)","volume":"29","author":"Staskin","year":"2018","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.euf.2024.09.012_b0245","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12955-018-0892-0","article-title":"Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)","volume":"16","author":"Herschorn","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.euf.2024.09.012_b0250","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.eururo.2012.10.048","article-title":"Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a \u03b23-adrenoceptor agonist, in overactive bladder","volume":"63","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.09.012_b0255","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/1756287215589250","article-title":"The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial","volume":"7","author":"Batista","year":"2015","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.euf.2024.09.012_b0260","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/nau.23919","article-title":"Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study","volume":"38","author":"Mueller","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2024.09.012_b0265","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.eururo.2018.05.005","article-title":"Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: a randomised, multicentre phase 3 study (SYNERGY II)","volume":"74","author":"Gratzke","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.09.012_b0270","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/iju.14608","article-title":"Effect of oxybutynin patch versus mirabegron on nocturia-related quality of life in female overactive bladder patients: a multicenter randomized trial","volume":"28","author":"Suzuki","year":"2021","journal-title":"Int J Urol"},{"key":"10.1016\/j.euf.2024.09.012_b0275","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/nau.23224","article-title":"Beta-3 adrenergic receptor is expressed in acetylcholine-containing nerve fibers of the human urinary bladder: an immunohistochemical study","volume":"36","author":"Coelho","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2024.09.012_b0280","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000445808","article-title":"Comparison of therapeutic efficacy and urodynamic findings of solifenacin succinate versus mirabegron in women with overactive bladder syndrome: results of a randomized controlled study","volume":"97","author":"Vecchioli Scaldazza","year":"2016","journal-title":"Urol Int"},{"key":"10.1016\/j.euf.2024.09.012_b0285","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.eururo.2016.02.030","article-title":"Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3b study (BESIDE)","volume":"70","author":"Drake","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.09.012_b0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.urology.2017.03.004","article-title":"Adding mirabegron to solifenacin to treat overactive bladder has little impact on postvoid residual volume or urinary retention risk","volume":"104","author":"Drake","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.euf.2024.09.012_b0295","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.12944","article-title":"Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE)","volume":"71","author":"Drake","year":"2017","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.euf.2024.09.012_b0300","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.euf.2017.08.008","article-title":"Treating overactive bladder in older patients with a combination of mirabegron and solifenacin: a prespecified analysis from the BESIDE study","volume":"3","author":"Gibson","year":"2017","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2024.09.012_b0305","first-page":"677","article-title":"Assessing preference-based outcome measures for overactive bladder: an evaluation of patient-reported outcome data from the BESIDE clinical trial","volume":"10","author":"Herdman","year":"2017","journal-title":"Patient"},{"key":"10.1016\/j.euf.2024.09.012_b0310","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.juro.2016.03.174","article-title":"Mirabegron as add-on treatment to solifenacin in patients with incontinent overactive bladder and an inadequate response to solifenacin monotherapy","volume":"196","author":"Scott","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2024.09.012_b0315","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/nau.24387","article-title":"The efficacy and safety of Vibegron in treating overactive bladder: a systematic review and pooled analysis of randomized controlled trials","volume":"39","author":"Shi","year":"2020","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2024.09.012_b0320","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000023171","article-title":"Systematic review and meta-analysis of the efficacy and safety of vibegron vs antimuscarinic monotherapy for overactive bladder","volume":"100","author":"Su","year":"2021","journal-title":"Medicine"},{"key":"10.1016\/j.euf.2024.09.012_b0325","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/luts.12475","article-title":"Efficacy and safety of vibegron compared with mirabegron for overactive bladder: a systematic review and network meta-analysis","volume":"15","author":"He","year":"2023","journal-title":"Low Urin Tract Symptoms"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456924001810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456924001810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:16:44Z","timestamp":1760073404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456924001810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2405456924001810"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2024.09.012","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mirabegron Versus Placebo and Other Therapeutic Modalities in the Treatment of Patients with Overactive Bladder Syndrome\u2014A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2024.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}